Adoption of Evidence-based clinical innovations

The case of buprenorphine use by opioid treatment programs

Christina M. Andrews, Thomas D'Aunno, Harold A. Pollack, Peter D. Friedmann

Research output: Contribution to journalArticle

Abstract

This article examines changes from 2005 to 2011 in the use of an evidence-based clinical innovation, buprenorphine use, among a nationally representative sample of opioid treatment programs and identifies characteristics associated with its adoption. We apply a model of the adoption of clinical innovations that focuses on the work needs and characteristics of staff; organizations' technical and social support for the innovation; local market dynamics and competition; and state policies governing the innovation. Results indicate that buprenorphine use increased 24% for detoxification and 47% for maintenance therapy between 2005 and 2011. Buprenorphine use was positively related to reliance on private insurance and availability of state subsidies to cover its cost and inversely related to the percentage of clients who injected opiates, county size, and local availability of methadone. The results indicate that financial incentives and market factors play important roles in opioid treatment programs' decisions to adopt evidence-based clinical innovations such as buprenorphine use.

Original languageEnglish (US)
Pages (from-to)43-60
Number of pages18
JournalMedical Care Research and Review
Volume71
Issue number1
DOIs
StatePublished - 2014

Fingerprint

Buprenorphine
Opioid Analgesics
Opiate Alkaloids
Methadone
Insurance
Social Support
Motivation
Organizations
Costs and Cost Analysis
Therapeutics

Keywords

  • adoption
  • buprenorphine
  • evidence-based practice
  • innovation
  • opioid treatment

ASJC Scopus subject areas

  • Health Policy

Cite this

Adoption of Evidence-based clinical innovations : The case of buprenorphine use by opioid treatment programs. / Andrews, Christina M.; D'Aunno, Thomas; Pollack, Harold A.; Friedmann, Peter D.

In: Medical Care Research and Review, Vol. 71, No. 1, 2014, p. 43-60.

Research output: Contribution to journalArticle

Andrews, Christina M. ; D'Aunno, Thomas ; Pollack, Harold A. ; Friedmann, Peter D. / Adoption of Evidence-based clinical innovations : The case of buprenorphine use by opioid treatment programs. In: Medical Care Research and Review. 2014 ; Vol. 71, No. 1. pp. 43-60.
@article{ed60a21842bc4b8a89e30dd3d5030e4d,
title = "Adoption of Evidence-based clinical innovations: The case of buprenorphine use by opioid treatment programs",
abstract = "This article examines changes from 2005 to 2011 in the use of an evidence-based clinical innovation, buprenorphine use, among a nationally representative sample of opioid treatment programs and identifies characteristics associated with its adoption. We apply a model of the adoption of clinical innovations that focuses on the work needs and characteristics of staff; organizations' technical and social support for the innovation; local market dynamics and competition; and state policies governing the innovation. Results indicate that buprenorphine use increased 24{\%} for detoxification and 47{\%} for maintenance therapy between 2005 and 2011. Buprenorphine use was positively related to reliance on private insurance and availability of state subsidies to cover its cost and inversely related to the percentage of clients who injected opiates, county size, and local availability of methadone. The results indicate that financial incentives and market factors play important roles in opioid treatment programs' decisions to adopt evidence-based clinical innovations such as buprenorphine use.",
keywords = "adoption, buprenorphine, evidence-based practice, innovation, opioid treatment",
author = "Andrews, {Christina M.} and Thomas D'Aunno and Pollack, {Harold A.} and Friedmann, {Peter D.}",
year = "2014",
doi = "10.1177/1077558713503188",
language = "English (US)",
volume = "71",
pages = "43--60",
journal = "Medical Care Research and Review",
issn = "1077-5587",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Adoption of Evidence-based clinical innovations

T2 - The case of buprenorphine use by opioid treatment programs

AU - Andrews, Christina M.

AU - D'Aunno, Thomas

AU - Pollack, Harold A.

AU - Friedmann, Peter D.

PY - 2014

Y1 - 2014

N2 - This article examines changes from 2005 to 2011 in the use of an evidence-based clinical innovation, buprenorphine use, among a nationally representative sample of opioid treatment programs and identifies characteristics associated with its adoption. We apply a model of the adoption of clinical innovations that focuses on the work needs and characteristics of staff; organizations' technical and social support for the innovation; local market dynamics and competition; and state policies governing the innovation. Results indicate that buprenorphine use increased 24% for detoxification and 47% for maintenance therapy between 2005 and 2011. Buprenorphine use was positively related to reliance on private insurance and availability of state subsidies to cover its cost and inversely related to the percentage of clients who injected opiates, county size, and local availability of methadone. The results indicate that financial incentives and market factors play important roles in opioid treatment programs' decisions to adopt evidence-based clinical innovations such as buprenorphine use.

AB - This article examines changes from 2005 to 2011 in the use of an evidence-based clinical innovation, buprenorphine use, among a nationally representative sample of opioid treatment programs and identifies characteristics associated with its adoption. We apply a model of the adoption of clinical innovations that focuses on the work needs and characteristics of staff; organizations' technical and social support for the innovation; local market dynamics and competition; and state policies governing the innovation. Results indicate that buprenorphine use increased 24% for detoxification and 47% for maintenance therapy between 2005 and 2011. Buprenorphine use was positively related to reliance on private insurance and availability of state subsidies to cover its cost and inversely related to the percentage of clients who injected opiates, county size, and local availability of methadone. The results indicate that financial incentives and market factors play important roles in opioid treatment programs' decisions to adopt evidence-based clinical innovations such as buprenorphine use.

KW - adoption

KW - buprenorphine

KW - evidence-based practice

KW - innovation

KW - opioid treatment

UR - http://www.scopus.com/inward/record.url?scp=84891866629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891866629&partnerID=8YFLogxK

U2 - 10.1177/1077558713503188

DO - 10.1177/1077558713503188

M3 - Article

VL - 71

SP - 43

EP - 60

JO - Medical Care Research and Review

JF - Medical Care Research and Review

SN - 1077-5587

IS - 1

ER -